Skip to main content
Caplight Logo









3Spine

3Spine

Private
Chattanooga, TennesseeHealthcare & Life Scienceshttps://3spine.com

Last Round

Series C

Extension

Feb 21, 2025

Total Funding Raised

$74.53M

Company Overview

3Spine operates in Healthcare & Life Sciences and is based in Chattanooga, Tennessee. Its latest recorded funding round was a Series C Extension round in February 2025.

3Spine is a medical device company that develops total joint replacement technology for the lumbar spine as an alternative to spinal fusion.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

3Spine Comparables

Compare 3Spine with similar companies based on industry and business-model similarity.

3Spine comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Premia Spine
89%
AxioMed
84%
Centinel Spine
84%
Book a demo to see all comparables

For institutional investors. Book with your work email.

3Spine Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionFeb 21, 2025
DebtApr 26, 2024
Series CMar 15, 2022
Series BJun 23, 2021
Series AAug 10, 2020
Series A
Jan 1, 2017
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Marc Peterman

CEO

Executive Team

Ron Yarbrough

COO 3Spine

Executive Team

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2017

    $7.3M round completed.

Book a demo to see all signals

For institutional investors. Book with your work email.

3Spine Filings

Explore SEC and related filing metadata, where available.

3Spine filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about 3Spine's valuation, stock price, and market status.

Is 3Spine a public or private company?

3Spine is a private company.

What is the current stock price of 3Spine?

3Spine is a private company, so its shares have no public market price. Caplight tracks 3Spine's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is 3Spine worth (valuation)?

Valuation information for 3Spine is not publicly available.

Can I buy 3Spine stock?

3Spine shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was 3Spine's last funding round?

3Spine's most recent funding round was Series C Extension on February 21, 2025.

Who are the main investors in 3Spine?

Investor information for 3Spine is not publicly disclosed.

Will 3Spine IPO soon?

No public IPO plans have been announced for 3Spine.

How can I track 3Spine secondary market activity?

Caplight tracks bids, offers, and trades in 3Spine's shares on secondary markets.

Firmographic Details

HeadquartersChattanooga, Tennessee
Employee Range15
Year Founded2017
Last FundingFeb 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?